Venous Pulmonary Waveforms in MitraClip Have Prognostic Value

Courtesy of Dr. Carlos Fava.

The MitraClip has been shown to benefit a certain group of patients and it is a well-known fact that a ≥5 mmHg is associated to a more torpid evolution. However, there is little evidence when it comes to venous pulmonary waves, changes in left atrial pressure and V wave.

121 patients with severe mitral regurgitation receiving MitraClip were retrospectively analyzed.

Mean age was 76, over 50% were men, 25% were diabetic, most were in functional class III-IV, 60% had atrial fibrillation and 43% ejection fraction.

The cause was degenerative in 64% of cases.

The number of implanted clips was 1.5, and it brought significant reduction of mitral regurgitation. Mortality was 8% with a low rate of complications.


Read also: Hours of Sleep and Myocardial Infarction Risk.


There was an increase in transmitral gradient (2.1 mmHg to 3.6 mmHg p <0.001) and in addition there was a reduction of left atrial pressure (23 mmHg to 19 mmHg p<0.001) and V wave (43 mmHg vs. 28 mmHg p<0.001). There was also improved S wave velocity after MictraClip.

Survival at 24 months was in favor of patients with improved pulmonary venous waves (85% vs. 40% p<0.001), all-cause mortality, and the composite of all cause death, need of left atrial assistance, reintervention, valve surgery and rehospitalization for cardiac failure.

Conclusion

Pulmonary venous waveforms are an important success marker after percutaneous mitral repair. These data chow that venous pulmonary waveforms might predict rehospitalization and mortality after percutaneous mitral repair. Large multicenter studies are called for to shed light on this matter.

Courtesy of Dr. Carlos Fava.

Original Title: Pulmonary Venous Waveforms Predict Rehospitalization and Mortality After Percutaneous Mitral Valve Repair.

Reference: Frank E. Corrigan, et al. JACC Cardiovsc Imag.DOI: 10.1016/j.jcmg.2018.07.014.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....